# A Study to Assess the Relative Oral Bioavailability of a Single Dose of JNJ-63623872/Oseltamivir Fixed-dose Combination Tablet and Single Agent Concept Formulations of JNJ-63623872 Compared to Their Respective Reference Formulation in Healthy Adult Participants

> **NCT03023852** · PHASE1 · COMPLETED · sponsor: **Janssen-Cilag International NV** · enrollment: 45 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** JNJ-63623872
- **DRUG:** Oseltamivir

## Key facts

- **NCT ID:** NCT03023852
- **Lead sponsor:** Janssen-Cilag International NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-14
- **Primary completion:** 2017-04-14
- **Final completion:** 2017-04-14
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2017-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03023852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03023852, "A Study to Assess the Relative Oral Bioavailability of a Single Dose of JNJ-63623872/Oseltamivir Fixed-dose Combination Tablet and Single Agent Concept Formulations of JNJ-63623872 Compared to Their Respective Reference Formulation in Healthy Adult Participants". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03023852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*